QPPV.COM KNOWLEDGE ASSESSMENT

Ofatumumab: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Ofatumumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which periodic benefit-risk assessment best reflects the article's recommended scope for current MS use?

Assess relapse and MRI control alone because efficacy determines overall benefit-risk Integrate disease control with infections, immunoglobulin trends, HBV, PML, injection reactions, pregnancy, vaccination and medication-error patterns Focus only on historical CLL outcomes because they involve the same molecule Evaluate all infections as one undifferentiated category without immune-status information

Question 2 of 10 Which follow-up information is most relevant when evaluating an apparent vaccination failure during ofatumumab treatment?

Vaccine type and date, interval from treatment, measured immune response if available and subsequent infection history Only the patient's injection-site reaction after the previous dose Only the brand colour of the vaccine packaging The patient's historical oncology diagnosis, regardless of whether it affected immune status

Question 3 of 10 Which aggregate-analysis strategy is most appropriate for ofatumumab safety data?

Pool all exposure eras and routes because the molecular target is identical Stratify historical oncology and current MS exposure by indication, route, dose and relevant background risks Analyse only reports with a serious outcome and exclude non-serious events Combine HBV reactivation with all hepatic adverse events to maximise case numbers

Question 4 of 10 Which variable is particularly important when interpreting infection risk in an MS patient who recently started ofatumumab after another high-efficacy disease-modifying therapy?

The prior therapy, its potential duration of immune effect and the washout interval Only the number of previous MRI scans Only whether ofatumumab was self-injected The historical oncology authorisation date, regardless of patient exposure

Question 5 of 10 Which mechanism is most consistent with the article's description of ofatumumab-mediated B-cell depletion?

Inhibition of viral DNA polymerase in B cells Complement-dependent cytotoxicity and antibody-dependent cellular mechanisms after binding CD20 Direct destruction of haematopoietic stem cells Blockade of immunoglobulin secretion by mature plasma cells

Question 6 of 10 Which biological feature most directly explains why ofatumumab produces substantial B-cell depletion without directly eliminating all long-lived antibody-producing plasma cells?

CD20 is expressed on plasma cells but not on mature B cells CD20 is expressed on relevant B-cell stages but is generally absent from terminally differentiated plasma cells Ofatumumab selectively blocks T-cell proliferation Plasma cells are protected because they do not contain immunoglobulin

Question 7 of 10 A patient develops a serious infection shortly after starting ofatumumab for MS. Which follow-up set would provide the strongest basis for causality and severity assessment?

Only the patient's age and injection-site preference Infection site and organism, microbiological confirmation, hospitalisation, immunoglobulins, lymphocyte or B-cell status, prior immunosuppressants and outcome Only the date of the most recent MRI Only whether the patient reported fatigue after injection

Question 8 of 10 Which pre-treatment approach is most consistent with the article's description of hepatitis B risk management?

Screen only patients who later develop abnormal liver tests Perform HBV screening including hepatitis B surface antigen and hepatitis B core antibody, followed by specialist assessment when serology is positive Avoid all HBV testing because B-cell depletion prevents viral replication Use only a general infection questionnaire without laboratory testing

Question 9 of 10 Why should a report of positive hepatitis B core antibody not automatically be coded or assessed as hepatitis B reactivation?

Core antibody testing is unrelated to hepatitis B risk Resolved prior infection, chronic infection and true reactivation are different clinical states requiring virological and clinical context HBV reactivation occurs only after vaccination Anti-CD20 therapies cannot be associated with HBV reactivation

Question 10 of 10 Which feature most helps distinguish a predictable injection-related reaction from a possible true hypersensitivity event?

Dose number, onset, systemic versus local symptom pattern, treatment and recurrence The patient's MS diagnosis alone Whether the historical oncology authorisation was withdrawn The patient's baseline MRI findings without symptom timing

Ofatumumab: Classification, History, Mechanism, Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings